valsartan has been researched along with Disease Models, Animal in 152 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (2.63) | 18.2507 |
| 2000's | 59 (38.82) | 29.6817 |
| 2010's | 69 (45.39) | 24.3611 |
| 2020's | 20 (13.16) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, Q; Li, G; Li, Y; Liu, T; Shao, S; Suo, Y; Wang, Y; Yang, Q; Yuan, M; Zhang, Y | 1 |
| Bin, J; Cao, S; Chen, L; He, M; Huang, X; Li, M; Liao, W; Liao, Y; Lin, H; Liu, C; Shen, M; Zheng, C | 1 |
| Choudhary, G; Clements, RT; Fernandez-Nicolas, A; Kue, NR; Mallem, K; Mancini, TJ; McCullough, DJ; Morrison, AR; Vang, A | 1 |
| Chang, PC; Chou, CC; Chu, Y; Huang, YC; Lee, HL; Lin, SF; Wen, MS; Wo, HT | 1 |
| Guo, BC; Huang, PH; Kuo, KL; Lee, TS; Tarng, DC; Zhao, JF | 1 |
| Ding, Z; Li, Y; Liu, R; Wang, Q; Zang, Y; Zhang, G; Zhang, X | 1 |
| Feng, H; Li, WJ; Liao, HH; Mou, SQ; Tang, QZ; Wu, HM; Xia, H; Zhang, N; Zhou, ZY | 1 |
| Ge, Q; Hu, Z; Liu, C; Pan, C; Ren, X; Yu, YH; Zhao, L | 1 |
| Jin, Q; Li, X; Wang, L; Wang, Q; Zhang, Q; Zheng, Y; Zhu, Q | 1 |
| Chen, X; Du, F; Gao, Z; Hua, H; Jing, X; Li, S; Sun, G; Sun, J; Xiao, Y; Xu, W | 1 |
| Ates, B; Colak, C; Ermis, N; Ozhan, O; Parlakpinar, H; Ulutas, Z; Vardi, N | 1 |
| Chaumais, MC; Cumont, A; Djessas, MRA; Gaignard, P; Guignabert, C; Hebert, G; Huertas, A; Humbert, M; Savale, L; Thuillet, R; Tu, L | 1 |
| Chen, L; Cheng, D; Li, Z; Meng, L; Tu, W; Wang, H; Wang, Q; Yu, Q | 1 |
| Haynes, R; Judge, PK | 1 |
| Hu, J; Liu, S; Liu, W; Lu, S; Wang, Y; Wang, Z; Zeng, X | 1 |
| Cao, Y; Chen, A; Chen, M; Fan, Y; Guan, X; Li, J; Liu, Y; Yang, D | 1 |
| Adams, V; Augstein, A; Barthel, P; Draskowski, R; Galli, R; Goto, K; Jannasch, A; Kirchhoff, V; Linke, A; Männel, A; Mittag, J; Schauer, A; Winzer, EB | 1 |
| Aroor, AR; Chandrasekar, B; Das, N; DeMarco, VG; Habibi, J; Jia, G; Lastra, G; Lopez-Alvarenga, JC; Mummidi, S | 1 |
| Chu, X; Guo, J; Li, Y; Liu, X; Peng, L; Sun, T; Tang, X; Xu, Q; Yang, X; Yu, H; Zhou, J | 1 |
| Abbate, A; Bhardwaj, H; Damonte, JI; Del Buono, MG; Markley, R; Salloum, FN; Trankle, CR; Turlington, J; Van Tassell, BW | 1 |
| Fan, Z; Qi, G; Shen, J; Sun, G | 1 |
| Braza, J; Choudhary, G; Li, X; Mende, U; Zhang, P | 1 |
| Chen, A; Chen, Z; Dong, Z; Fu, M; Ge, J; Hu, K; Qian, J; Sun, A; Xia, Y; Yang, X; Zou, Y | 1 |
| Černe, D; Drevenšek, G; France Štiglic, A; Janić, M; Jerin, A; Lunder, M; Marc, J; Šabovič, M; Skitek, M | 1 |
| Goto, K; Kansui, Y; Kitazono, T; Matsumura, K; Ohtsubo, T; Seki, T | 1 |
| Chen, L; Li, C; Li, M; Liu, XC; Qiu, CG; Wang, W; Yan, KP | 1 |
| Jing, W; Kashyap, ML; Khazaeli, M; Moradi, H; Nunes, A; Suematsu, Y; Vaziri, ND | 1 |
| Dalman, RL; Iida, Y; Miyata, M; Xu, B; Xuan, H | 1 |
| Goodchild, TT; Koiwaya, H; Lefer, DJ; Li, Z; Polhemus, DJ; Scarborough, A; Trivedi, RK; Yoo, D | 1 |
| Kelly, DJ; Kompa, AR; Krum, H; Lu, J; von Lueder, TG; Wang, BH; Weller, TJ | 1 |
| Akagi, S; Ito, H; Kondo, M; Miura, D; Miyoshi, T; Nakamura, K; Ohno, Y; Saito, Y; Yoshida, M | 1 |
| Bian, Q; Guo, L; Liang, T; Liu, J; Luo, B; Niu, J; Song, Q; Wei, Q; Zhang, K | 1 |
| Li, CZ; Li, DS; Li, PH; Li, SX; Li, Y; Lu, YJ; Pan, ZW; Shi, L; Su, WZ; Sun, YL; Xue, GL; Zhang, Y; Zhao, Y; Zhou, Y | 1 |
| Aykan, DA; Eser, N; Koca, TT; Yaman, S | 1 |
| Hamano, G; Moritani, T; Rakugi, H; Shimosato, T; Takami, Y; Takeshita, H; Yamamoto, K | 1 |
| Aroor, AR; Chandrasekar, B; Das, NA; DeMarco, VG; Habibi, J; Hayden, MR; Johnson, MS; Manrique-Acevedo, CM; Nistala, R; Wiedmeyer, C | 1 |
| Li, N; Ma, R; Yu, J; Yu, X; Zhao, X; Zhao, Y | 1 |
| Badole, S; Di Carli, M; Divakaran, S; Eroglu, E; Kijewski, MF; Michel, T; Saravi, SSS; Sorrentino, A; Steinhorn, B; Troncone, L | 1 |
| Andersen, A; Andersen, S; Axelsen, JB; Bogaard, HJ; de Man, FS; Hyldebrandt, JA; Nielsen-Kudsk, JE; Nyengaard, JR; Ringgaard, S | 1 |
| Crane, JA; Ebrahimi, B; Eirin, A; Jordan, KL; Krier, JD; Lerman, A; Lerman, LO; Li, ZL; Pawar, AS; Tang, H; Textor, SC; Zhang, X; Zhu, XY | 1 |
| Hang, P; Li, Y; Sun, D; Sun, L; Wang, X; Xu, W; Yun, F; Zhao, H; Zhao, J | 1 |
| Hatou, S; Imada, T; Ishida, S; Kawakami, Y; Kawakita, T; Miyashita, H; Mori, T; Nakamura, S; Ogawa, Y; Okamoto, S; Ozawa, Y; Satofuka, S; Shimmura, S; Tsubota, K; Yaguchi, S; Yaguchi, T; Yoshida, S | 1 |
| Chang, KH; Dikalova, AE; Engberding, N; Griendling, KK; Jo, H; Koga, M; Lassègue, B; Long, JS; Seidel-Rogol, B | 1 |
| Araki, E; Goto, R; Igata, M; Kawasaki, S; Kawashima, J; Kitano, S; Kondo, T; Matsumura, T; Matsuyama, R; Miyagawa, K; Motoshima, H; Ono, K | 1 |
| Baker, KM; Chandel, N; Kumar, R; Seqqat, R; Thomas, CM; Yong, QC | 1 |
| Ahad, A; Ali, A; Aqil, M | 1 |
| Chen, G; He, QY; Pan, SF; Pan, SQ; Shen, C; Zhang, XM | 1 |
| Feng, GF; Han, H; Hu, XD; Liu, Y; Qian, YH; Shi, LL; Yang, WN | 1 |
| Fletcher, EL; Hatzopoulos, KM; Vessey, KA; Wilkinson-Berka, JL | 1 |
| Dong, W; Gong, G; Lin, X; Wang, X; Yang, B; Yang, Y; Yuan, B | 1 |
| Huo, Y; Lei, L; Mao, Y; Meng, L; Qi, Y; Su, J; Tang, C | 1 |
| Atar, D; Huang, L; Jordaan, P; Kompa, AR; Krum, H; von Lueder, TG; Wang, BH; Webb, R | 1 |
| Jo, CH; Simoni, J; Wesson, DE | 1 |
| Ahn, Y; Bom, HS; Cho, JG; Cho, JY; Chong, A; Hong, YJ; Jang, SY; Jeong, HC; Jeong, IS; Jeong, MH; Kang, JC; Kim, HK; Kim, J; Kim, JH; Kim, JM; Kim, KH; Kim, MS; Kim, SS; Lee, KH; Lim, KS; Oh, SG; Park, DS; Park, HW; Park, JC; Park, KH; Ryu, SH; Sim, DS; Song, HC; Yoon, HJ; Yoon, NS | 1 |
| Chai, M; Dong, Z; Ji, Q; Lin, Y; Liu, Y; Lu, Q; Meng, K; Wu, B; Yu, K; Zeng, Q; Zhang, J; Zhou, Y | 1 |
| Cheng, WP; Lo, HM; Shyu, KG; Wang, BW | 1 |
| Akhter, N; Huda, S | 1 |
| Li, KY; Zhang, YJ | 1 |
| Chen, JH; Chen, LL; Chen, XH; Fu, FY; Tang, MR; Wang, WW; Zhang, FL | 1 |
| Bono, E; Castiglioni, L; Colazzo, F; Colombo, GI; Fontana, L; Guerrini, U; Milano, G; Paleari, S; Palermo, A; Piacentini, L; Sironi, L; Tremoli, E | 1 |
| Cheng, W; Hu, H; Li, X; Wang, Y; Xuan, Y; Xue, M; Yan, S; Yang, N; Yin, J | 2 |
| DeKosky, ST; Feldman, AM; Haller, JA | 1 |
| Chen, S; Levi, M; Li, C; Lin, Y; Luo, R; Wang, F; Wang, W; Yang, T; Zheng, P | 1 |
| Gu, Y; Liu, XY; Wang, H; Wu, J; Zhang, MJ; Zhu, PF | 1 |
| Figueira, L; Israel, A | 1 |
| Jia, S; Liu, XL; Ma, Y; Peng, PA; Sun, Y; Wu, SJ; Xu, XH; Yu, Y; Zhou, YJ | 1 |
| Ameer, OZ; Avolio, AP; Butlin, M; Kaschina, E; Phillips, JK; Sommerfeld, M | 1 |
| Argani, H; Bargahi, N; Dastmalchi, S; Ghasemi, B; Ghazizadeh, T; Ghorbanihaghjo, A; Mesgari Abbasi, M; Mota, A; Nemati, M; Raeisi, S; Rashtchizadeh, N; Vatankhah, AM | 1 |
| Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z | 1 |
| Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K | 1 |
| Chen, B; Guan, GJ; Hou, XH; Li, XG; Liu, G; Liu, JL; Zhang, Y | 1 |
| Baker, AB; Beigel, R; Chatzizisis, YS; Coskun, AU; Daley, W; Edelman, ER; Feldman, CL; Gerrity, RG; Jonas, M; Maynard, C; Stone, BV; Stone, PH | 1 |
| Bozkurt, D; Cetin, P; Duman, S; Ertilav, M; Hur, E; Nar, H; Sezak, M; Sipahi, S | 1 |
| Aoki, M; Fujiwara, Y; Makino, H; Miyake, T; Morishita, R; Nishimura, M; Shiraya, S; Yamakawa, S | 1 |
| Bader, M; Carretero, OA; Rhaleb, NE; Shesely, EG; Xu, J; Yang, JJ; Yang, XP | 1 |
| Dai, Y; Deng, W; Su, L; Yin, YH | 1 |
| Chihara, K; Dan, T; Izuhara, Y; Kurokawa, K; Miyata, T; Ohtomo, S; Robert, A; Tominaga, N; Van Ypersele de Strihou, C | 1 |
| Fan, H; Liu, X; Wang, A; Yuan, H; Zhu, X | 1 |
| Han, LH; Jiang, B; Jiang, WP; Li, HX; Liu, ZH; Qu, FZ; Zou, C | 1 |
| Guan, Q; Pang, X; Sun, D; Xie, L; Zeng, D; Zhang, H | 1 |
| Biala, A; Eriksson, O; Finckenberg, P; Kaheinen, P; Lapatto, R; Lempiäinen, J; Louhelainen, M; Luft, FC; Martonen, E; Mattila, I; Merasto, S; Mervaala, E; Muller, DN; Oresic, M | 1 |
| Carter, JD; Cole, BK; Keller, SR; Nadler, JL; Nunemaker, CS; Wu, R | 1 |
| Fu, L; Gao, Q; Li, Y; Ma, D | 1 |
| Binger, KJ; Campbell, DJ; Cooper, ME; Fletcher, EL; Hatzopoulos, KM; Heine, R; Miller, AG; Tan, G; Wilkinson-Berka, JL | 1 |
| Brown, RE; Imran, SA; Wilkinson, M | 1 |
| Carretero, OA; Liao, TD; Liu, TS; Peng, H; Reudelhuber, TL; Shesely, EG; Xu, J; Yang, JJ; Yang, XP | 1 |
| Aritomi, S; Koganei, H; Konda, T; Mitsui, A; Nitta, K; Ogawa, T; Wagatsuma, H | 1 |
| Furuno, M; Higaki, J; Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Okayama, H; Senba, I | 1 |
| Imig, JD; Khan, AH | 1 |
| Hirooka, Y; Hoka, S; Ito, K; Kishi, T; Nakagaki, T; Sunagawa, K | 1 |
| Ahad, A; Ali, A; Aqil, M; Kohli, K; Mujeeb, M; Sultana, Y | 1 |
| Jing, L; Lu, LX; Sang, Y; Yuan, L; Zhang, QH; Zhou, LJ | 1 |
| Ahmad, S; Ferrario, CM; Moniwa, N; Varagic, J; VonCannon, JL | 1 |
| Binger, KJ; Deliyanti, D; Miller, AG; Samson, AL; Tan, G; Wilkinson-Berka, JL | 1 |
| Altieri, PI; Cangiano, JL; Crespo, MJ; Escobales, N | 1 |
| Abe, S; Furusho, Y; Hamasaki, S; Ikeda, Y; Kajiya, S; Kihara, K; Lee, S; Minagoe, S; Miyata, M; Nakamura, S; Ohba, I; Sasaki, T; Tateishi, S; Tei, C; Torii, H | 1 |
| Aono, J; Higaki, J; Horiuchi, M; Inoue, K; Iwai, M; Nagai, T; Nishimura, K; Ogimoto, A; Okayama, H; Suzuki, J | 1 |
| Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM | 1 |
| Amedeo Modesti, P; Bertolozzi, I; Boddi, M; Cecioni, I; Coppo, M; Formigli, L; Perna, AM; Polidori, G; Serneri, GG; Vanni, S; Zecchi-Orlandini, S | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H | 1 |
| Chan, P; Cheng, JT; Liu, IM; Tzeng, TF; Wong, KL; Yang, TL | 1 |
| Bedigian, MP; Lu, L; Robinson, AD; Sun, Y; Weber, KT; Zhang, J | 1 |
| Jugdutt, BI; Menon, V | 1 |
| Katayama, S; Morita, T; Yagi, S | 1 |
| Cui, TX; Horiuchi, M; Iwai, M; Li, HS; Li, JM; Min, LJ; Okumura, M; Shiuchi, T; Wu, L | 1 |
| Chen, R; Cui, TX; Gao, XY; Horiuchi, M; Iwai, M; Jinno, T; Li, Z; Liu, HW; Okumura, M; Suzuki, J; Tsuda, M; Wu, L | 1 |
| Jugdutt, BI; Menon, V; Sawicki, G | 1 |
| Bahtyiar, G; Blendea, MC; Ferrario, CM; Jacobs, D; Kumar, P; McFarlane, SI; Ogrin, C; Sha, Q; Sowers, JR; Stas, S; Stump, CS | 1 |
| Inoguchi, T; Kobayashi, K; Maeda, Y; Nakayama, M; Nawata, H; Sasaki, S; Sawada, F; Sonoda, N; Sonta, T; Sumimoto, H; Tsubouchi, H | 1 |
| DI, J; Huang, ST; Lei, XY; Li, JM; Lu, YS | 1 |
| Chen, YP; Dong, HR; Qiu, CB; Zhang, C | 1 |
| Laverty, R; Ledingham, JM | 1 |
| Bai, XJ; Qi, ZM; Wang, HX; Zhang, YJ | 1 |
| Adachi, Y; Hirouchi, M; Hu, Z; Maeda, K; Sugiyama, Y; Yamashiro, W | 1 |
| Chowdhury, NA; Cooper, SA; Ferrario, C; Gallagher, PE; Habibi, J; Hayden, MR; Link, CD; Sowers, JR; Stump, CS; Tallant, EA; Whaley-Connell, AT; Wiedmeyer, CE | 1 |
| Cesolari, JA; Laudanno, OM | 1 |
| Chen, N; Hao, L; Sun, G; Wang, W; Wu, K; Zhang, Y; Zhou, T | 1 |
| Akdag, I; Filiz, G; Gullulu, M; Kahvecioglu, S; Savci, V | 1 |
| Akasaka, T; Goto, M; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Yoshida, K | 1 |
| Chu, S; Dong, D; Gong, YT; Han, W; Li, BX; Li, WM; Li, Y; Liu, W; Sheng, L; Xue, JY; Yang, BF; Zhang, L | 1 |
| Gaskin, FS; Kamada, K; Korthuis, RJ; Yusof, M | 1 |
| Chen, S; Huang, H; Li, R; Liu, P; Tang, F; Wang, P; Zhang, H | 1 |
| Benetos, A; Cattan, V; Labat, C; Lacolley, P; Louis, H; Mercier, N; Safar, ME | 1 |
| Itoh, Y; Mori, Y; Tajima, N | 1 |
| Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kondo, T; Li, L; Li, Y; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Ohno, T; Okada, H; Takemura, G | 1 |
| Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Maeyama, S; Mawatari, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M | 1 |
| Cui, RZ; Liu, GQ; Mao, YM; Sun, GY; Sun, J; Zhang, SS; Zhao, HM | 1 |
| Azuma, J; Dosaka, N; Iekushi, K; Katsuragi, N; Koibuchi, N; Morishita, R; Nagao, K; Ogihara, T; Sanada, F; Taniyama, Y | 1 |
| Chen, K; Clark, SE; Ferrario, CM; Habibi, J; Sowers, JR; Stump, CS; Uptergrove, GM; Wei, Y; Whaley-Connell, AT | 1 |
| Burstein, B; Calderone, A; Nattel, S; Qi, XY; Yeh, YH | 1 |
| Dong, YF; Ichijo, H; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Ogawa, H; Shintaku, H; Tokutomi, Y; Yamamoto, E; Yamashita, T | 1 |
| Bartholomew, S; Chen, L; Ho, L; Humala, N; Pasinetti, GM; Qian, X; Rosendorff, C; Seror, I; Wang, J; Zhao, W; Zhao, Z | 1 |
| Guan, YY; Liu, YJ; Lu, HH; Sheng, ZQ; Wang, Y; Zhang, L | 1 |
| Appleyard, CB; Ferder, L; Rivera, E; Santiago, OI | 1 |
| Horiuchi, M; Inaba, S; Iwai, M; Mogi, M; Tomono, Y | 1 |
| Jin, D; Kimura, M; Kirimura, K; Miyazaki, M; Sakonjo, H; Takai, S; Tanaka, K | 1 |
| Asai, S; Ishikawa, K; Nishida, Y; Sugahara-Kobayashi, M; Takahashi, Y | 1 |
| Liu, ZY; Sun, GY; Zhang, SS | 1 |
| Clark, SE; Ferrario, CM; Ibdah, JA; Morris, EM; Sowers, JR; Thyfault, JP; Uptergrove, GM; Wei, Y; Whaley-Connell, AT | 1 |
| Clair, MJ; de Gasparo, M; Hebbar, L; Iannini, JP; Krombach, RS; Melton, DM; Mukherjee, R; O, SJ; Spinale, FG; Whitebread, S | 1 |
| Davis, S; de Gasparo, M; Navarrete, AE; Webb, RL | 1 |
| Clair, MJ; de Gasparo, M; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Rios, G; Spinale, FG; Whitebread, S | 1 |
| Arai, Y; Hirose, N; Kawamura, M; Li, J | 1 |
| Basset, A; Blanc, J; Elghozi, JL | 1 |
| Cooper, ME; Gilbert, RE; Huang, XR; Johnson, RJ; Lai, KN; Lan, HY; Wu, LL; Yang, N; Yu, XQ | 1 |
| Iwao, H; Izumi, Y; Kawano, H; Kim, S; Kimoto, M; Yoshiyama, M; Zhan, Y | 1 |
| Sandmann, S; Unger, T; Yu, M | 1 |
| Cheng, ZJ; Fiebeler, A; Ganten, D; Ganten, U; Lapatto, R; Luft, FC; Mervaala, EM; Müller, DN; Nurminen, K; Tikkanen, I; Vapaatalo, H | 1 |
| Allen, TJ; Bertram, JF; Cooper, ME; Gilbert, RE; Hulthen, UL; Kelly, DJ; Mifsud, SA; Wilkinson-Berka, JL | 1 |
| Hartner, A; Hilgers, KF; Mann, JF; Porst, M; Veelken, R | 1 |
| Cachofeiro, V; Cediel, E; de Las Heras, N; Lahera, V; Oubiña, MP; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S | 1 |
2 review(s) available for valsartan and Disease Models, Animal
| Article | Year |
|---|---|
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2021 |
Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm, Abdominal; Aortic Rupture; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Humans; Receptor, Angiotensin, Type 1; Telmisartan; Valsartan | 2018 |
1 trial(s) available for valsartan and Disease Models, Animal
| Article | Year |
|---|---|
Effects of valsartan on fibrinolysis in hypertensive patients with metabolic syndrome.
Topics: Adipocytes; Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Apolipoproteins E; Biomarkers; Cardiovascular Diseases; Disease Models, Animal; Female; Fibrinolysis; Humans; Hypertension; Japan; Male; Metabolic Syndrome; Mice; Mice, Knockout; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2012 |
149 other study(ies) available for valsartan and Disease Models, Animal
| Article | Year |
|---|---|
Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Diastole; Disease Models, Animal; Drug Combinations; Heart Failure; Mice; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction | 2022 |
LCZ696 (sacubitril/valsartan) inhibits pulmonary hypertension induced right ventricular remodeling by targeting pyruvate dehydrogenase kinase 4.
Topics: Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Glycogen Synthase Kinase 3 beta; Heart Failure; Hypertension, Pulmonary; Male; Mice; Molecular Docking Simulation; Valsartan; Ventricular Remodeling | 2023 |
Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial Pressure; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Female; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Neprilysin; Protease Inhibitors; Pulmonary Artery; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Vascular Remodeling; Ventricular Dysfunction, Right; Ventricular Function, Right; Ventricular Remodeling | 2019 |
LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model.
Topics: Aminobutyrates; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; ERG1 Potassium Channel; Female; Heart Failure; Heart Rate; Heart Ventricles; Male; Myocardial Infarction; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channels, Voltage-Gated; Rats, Sprague-Dawley; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2019 |
Indoxyl sulfate impairs valsartan-induced neovascularization.
Topics: Animals; Cell Line; Disease Models, Animal; Hindlimb; Humans; Indican; Ischemia; Male; Mice; Neovascularization, Physiologic; Nephrectomy; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase C-alpha; Signal Transduction; Valsartan | 2020 |
Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-β1 Signaling in Kidney.
Topics: Animals; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Drug Synergism; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Renal Insufficiency, Chronic; Signal Transduction; Silybin; Transforming Growth Factor beta1; Valsartan | 2020 |
Combination treatment of perifosine and valsartan showed more efficiency in protecting against pressure overload induced mouse heart failure.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Glycogen Synthase Kinase 3 beta; Heart Failure; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Organ Size; Phosphorylcholine; Pressure; Proto-Oncogene Proteins c-akt; Signal Transduction; Valsartan | 2020 |
LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Biphenyl Compounds; Cardiomegaly; Constriction, Pathologic; Disease Models, Animal; Drug Combinations; Fibrosis; Male; Mice; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan | 2020 |
Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Fibrosis; Hypertrophy, Left Ventricular; Inflammasomes; Male; Mice, Inbred C57BL; Myocardium; Neprilysin; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Protease Inhibitors; Signal Transduction; Tetrazoles; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
Topics: Administration, Oral; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiomegaly; Chronic Disease; Disease Models, Animal; Dogs; Drug Combinations; Heart Failure; Myocardial Ischemia; Neprilysin; Protease Inhibitors; Rats, Sprague-Dawley; Recovery of Function; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2020 |
The Protective Effects of Compound 21 and Valsartan in Isoproterenol-Induced Myocardial Injury in Rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Drug Therapy, Combination; Heart Failure; Heart Rate; Isoproterenol; Male; Myocardium; Rats, Wistar; Receptor, Angiotensin, Type 2; Stroke Volume; Sulfonamides; Thiophenes; Valsartan; Ventricular Function, Left | 2021 |
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Bosentan; Cell Proliferation; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neprilysin; Protease Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Wistar; Valsartan; Vascular Remodeling | 2021 |
Protective effects of valsartan administration on doxorubicin‑induced myocardial injury in rats and the role of oxidative stress and NOX2/NOX4 signaling.
Topics: Animals; Apoptosis; Cardiotoxicity; Cell Line; Disease Models, Animal; Doxorubicin; Gene Expression Regulation; Heart Function Tests; Male; NADPH Oxidase 2; NADPH Oxidase 4; Oxidative Stress; Random Allocation; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Valsartan | 2020 |
Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Body Weight; Disease Models, Animal; Disease Progression; Drug Combinations; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Rats; Rats, Sprague-Dawley; Tetrazoles; Valsartan | 2021 |
Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Fibrosis; Heart Failure; Hemodynamics; Inflammation Mediators; Male; Mice, Inbred C57BL; Myocardial Contraction; Myocardial Infarction; Myocardium; Neprilysin; Protease Inhibitors; Renin; Tetrazoles; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Connectin; Cyclic GMP; Diastole; Disease Models, Animal; Drug Combinations; Electrocardiography; Female; Fibrosis; Glycated Hemoglobin; Heart Failure; Muscle, Skeletal; Muscular Atrophy; Natriuretic Peptide, Brain; Peptide Fragments; Phosphorylation; Rats, Mutant Strains; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cytokines; Diabetic Cardiomyopathies; Diastole; Disease Models, Animal; Drug Combinations; Male; Myocardium; Neprilysin; Obesity; Protease Inhibitors; Rats, Zucker; Valsartan; Vascular Stiffness; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Valsartan Prevented Neointimal Hyperplasia and Inhibited SRSF1 Expression and the TLR4-iNOS-ERK-AT1 Receptor Pathway in the Balloon-injured Rat Aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Hyperplasia; Male; Neointima; Nitric Oxide Synthase Type II; Phosphorylation; Rats, Wistar; Receptor, Angiotensin, Type 1; Serine-Arginine Splicing Factors; Signal Transduction; Toll-Like Receptor 4; Valsartan; Vascular System Injuries | 2021 |
Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Clinical Decision-Making; Disease Models, Animal; Drug Combinations; Evidence-Based Medicine; Heart Disease Risk Factors; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Protease Inhibitors; Protective Factors; Risk Assessment; Treatment Outcome; Valsartan | 2021 |
Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3‑induced pyroptosis via the TAK1/JNK signaling pathway.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cardiotonic Agents; Caspases; Cell Line; Cytokines; Disease Models, Animal; Drug Combinations; Heart Injuries; Inflammasomes; Inflammation; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinases; Myocardial Infarction; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Phosphate-Binding Proteins; Pyroptosis; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Valsartan | 2021 |
Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Aorta; Biphenyl Compounds; Cardiotonic Agents; Constriction; Disease Models, Animal; Drug Combinations; Early Medical Intervention; Fibroblasts; Fibrosis; Heart Ventricles; Male; Mitochondria, Heart; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Sprague-Dawley; RNA, Messenger; Superoxides; Valsartan; Ventricular Remodeling | 2021 |
LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Apoptosis; Biphenyl Compounds; Cardiomyopathy, Dilated; Cells, Cultured; Disease Models, Animal; Doxorubicin; Drug Combinations; Dynamins; Echocardiography; Female; Gene Expression; Humans; Male; Mice; Mitochondria; Myocytes, Cardiac; Tetrazoles; Valsartan; Ventricular Dysfunction | 2017 |
Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arginine; Blood Pressure; Cholesterol; Coronary Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Male; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Rats, Wistar; Receptor, Endothelin A; Time Factors; Valsartan; Vasodilation | 2017 |
Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Endothelium, Vascular; Hypertension; KATP Channels; Male; Membrane Potentials; Mesenteric Artery, Superior; Neprilysin; Protease Inhibitors; Rats, Inbred SHR; Renin-Angiotensin System; Signal Transduction; Tetrazoles; Time Factors; Valsartan; Vasodilation; Vasodilator Agents | 2017 |
Valsartan regulates TGF-β/Smads and TGF-β/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure.
Topics: Animals; Antihypertensive Agents; Apoptosis; Cells, Cultured; Disease Models, Animal; Doxorubicin; Heart Failure; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; RNA, Long Noncoding; Smad Proteins; Transforming Growth Factor beta1; Valsartan | 2018 |
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Disease Models, Animal; Drug Combinations; Fibrosis; Heart Failure; Male; Neprilysin; Random Allocation; Rats; Rats, Sprague-Dawley; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Heart Failure; Hypertension; Male; Myocardium; Natriuretic Peptides; Neprilysin; Nitric Oxide; Protease Inhibitors; Rats, Inbred SHR; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2018 |
Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Cardiotonic Agents; Disease Models, Animal; Drug Combinations; Male; Myocardial Infarction; Neprilysin; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Valsartan | 2018 |
Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Fibrosis; Hemodynamics; Humans; Hypertrophy, Left Ventricular; Isoproterenol; Myocardium; Neprilysin; Protease Inhibitors; Rats, Wistar; Tetrazoles; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2019 |
The probable roles of valsartan in alleviating chronic obstructive pulmonary disease following co-exposure to cold stress and fine particulate matter.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Animals; Cold Temperature; Deoxyguanosine; Disease Models, Animal; Gene Expression Regulation; Heme Oxygenase-1; Humans; Male; Malondialdehyde; NF-kappa B; Particulate Matter; Pulmonary Disease, Chronic Obstructive; Rats; Tumor Necrosis Factor-alpha; Valsartan | 2018 |
Valsartan reduced the vulnerability to atrial fibrillation by preventing action potential prolongation and conduction slowing in castrated male mice.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Cells, Cultured; Connexin 43; Disease Models, Animal; Heart Conduction System; Heart Rate; Male; Mice, Inbred ICR; Myocytes, Cardiac; Orchiectomy; Potassium; Sodium; Testosterone; Time Factors; Valsartan | 2018 |
Angiotensin converting enzyme and neprilysin inhibition alter pain response in dexhamethasone-induced hypertensive rats.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dexamethasone; Disease Models, Animal; Drug Combinations; Hypertension; Male; Neprilysin; Pain; Pain Threshold; Peptidyl-Dipeptidase A; Ramipril; Rats; Rats, Wistar; Renin-Angiotensin System; Tetrazoles; Valsartan | 2019 |
Effects of Low-Dose Sacubitril/Valsartan on Different Stages of Cardiac Hypertrophy in Salt-Loaded Hypertensive Rats.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Disease Models, Animal; Drug Combinations; Gene Expression Regulation; Kidney; Male; Neprilysin; Protease Inhibitors; Pulmonary Edema; Rats, Inbred SHR; Sodium Chloride, Dietary; Tetrazoles; Valsartan | 2019 |
The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Biomarkers; Biphenyl Compounds; Blood Glucose; Diabetic Nephropathies; Disease Models, Animal; Drug Combinations; Fibrosis; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Neprilysin; Nitrosative Stress; Oxidative Stress; Protease Inhibitors; Proteinuria; Rats, Zucker; Tetrazoles; Time Factors; Valsartan | 2019 |
AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Drug Combinations; Female; Fibrosis; Gene Expression Regulation; Hypertension; Hypertrophy, Left Ventricular; Myocytes, Cardiac; Neprilysin; Oxidative Stress; Protease Inhibitors; Rats, Inbred SHR; Rats, Inbred WKY; Renin-Angiotensin System; Signal Transduction; Tetrazoles; Valsartan; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Biphenyl Compounds; Cardiomyopathy, Dilated; D-Amino-Acid Oxidase; Dependovirus; Disease Models, Animal; Drug Combinations; Energy Metabolism; Fungal Proteins; Genetic Vectors; Hydrogen Peroxide; Injections, Intravenous; Male; Mitochondria, Heart; Myocytes, Cardiac; Neprilysin; Oxidative Stress; Promoter Regions, Genetic; Protease Inhibitors; Rats, Wistar; Tetrazoles; Troponin T; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.
Topics: Aminobutyrates; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Pulmonary Circulation; Rats; Tetrazoles; Valsartan; Vascular Remodeling; Ventricular Dysfunction, Right | 2019 |
Angiotensin receptor blockade has protective effects on the poststenotic porcine kidney.
Topics: Acute Kidney Injury; Angiotensin Receptor Antagonists; Animals; Constriction, Pathologic; Disease Models, Animal; Female; Glomerular Filtration Rate; Hemodynamics; Kidney; Microcirculation; Oxidative Stress; Receptors, Angiotensin; Renal Artery Obstruction; Swine; Tetrazoles; Valine; Valsartan | 2013 |
Valsartan inhibits transient receptor potential canonical-3 channel in canine atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Disease Models, Animal; Dogs; Tetrazoles; TRPC Cation Channels; Valine; Valsartan | 2013 |
Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Gene Expression; Graft vs Host Disease; Histocompatibility Testing; Humans; Imidazoles; Lacrimal Apparatus; Liver; Lung; Male; Mice; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2013 |
The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Bone Morphogenetic Proteins; Carrier Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Male; Mice; Mice, Mutant Strains; Reactive Oxygen Species; Tetrazoles; Valine; Valsartan; Vasculitis | 2013 |
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Topics: Adamantane; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Homeodomain Proteins; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Phlorhizin; Pyrrolidines; Tetrazoles; Trans-Activators; Valine; Valsartan; Vildagliptin | 2013 |
Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Disease Models, Animal; Down-Regulation; Fumarates; Kallikreins; Kininogens; Kinins; Mice; Mice, Knockout; Myocytes, Cardiac; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Tetrazoles; Ultrasonography; Valine; Valsartan | 2013 |
Investigation of antihypertensive activity of carbopol valsartan transdermal gel containing 1,8-cineole.
Topics: Acrylic Resins; Administration, Cutaneous; Animals; Antihypertensive Agents; Blood Pressure; Chemistry, Pharmaceutical; Cyclohexanols; Disease Models, Animal; Eucalyptol; Gels; Monoterpenes; Rats; Skin; Tetrazoles; Valine; Valsartan | 2014 |
Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-κB pathways.
Topics: Administration, Oral; Angiotensin II; Animals; Antioxidants; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypertrophy, Left Ventricular; Isoflavones; Male; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; NF-kappa B; Oxidation-Reduction; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Reactive Oxygen Species; Signal Transduction; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Remodeling | 2014 |
The effects of valsartan on cognitive deficits induced by aluminum trichloride and d-galactose in mice.
Topics: Acetylcholinesterase; Aluminum Chloride; Aluminum Compounds; Animals; Cerebral Cortex; Chlorides; Cognition Disorders; Dementia; Disease Models, Animal; Galactose; Glutathione Peroxidase; Hippocampus; Malondialdehyde; Maze Learning; Memory Disorders; Mice; Nootropic Agents; Oxidative Stress; Random Allocation; Superoxide Dismutase; Tetrazoles; Valine; Valsartan | 2014 |
The vasoneuronal effects of AT1 receptor blockade in a rat model of retinopathy of prematurity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Disease Models, Animal; Electroretinography; Female; Fluorescent Antibody Technique, Indirect; Microglia; Microscopy, Confocal; Oxygen; Photic Stimulation; Photoreceptor Cells, Vertebrate; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Retinal Neovascularization; Retinal Vessels; Retinopathy of Prematurity; Tetrazoles; Valine; Valsartan | 2014 |
Humid heat exposure induced oxidative stress and apoptosis in cardiomyocytes through the angiotensin II signaling pathway.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Apoptosis; Disease Models, Animal; Female; Heat Stress Disorders; HEK293 Cells; Hot Temperature; Humans; Humidity; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Oxidative Stress; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Signal Transduction; Time Factors; Valsartan | 2015 |
Impaired regulator of G protein signaling 2 transcription facilitates vascular remodeling in injured rat aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Male; Muscle, Smooth, Vascular; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Tetrazoles; Valine; Valsartan; Vascular Remodeling; Vascular System Injuries | 2014 |
Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Drug Combinations; Fibrosis; Male; Myocardial Infarction; Myocardium; Neprilysin; Rats; Rats, Sprague-Dawley; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Angiotensin II-mediated GFR decline in subtotal nephrectomy is due to acid retention associated with reduced GFR.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animal Feed; Animals; Disease Models, Animal; Female; Glomerular Filtration Rate; Kidney; Male; Microdialysis; Nephrectomy; Protons; Rats; Rats, Wistar; Sodium Bicarbonate; Tetrazoles; Valine; Valsartan | 2015 |
Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction.
Topics: 3-Iodobenzylguanidine; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anterior Wall Myocardial Infarction; Biphenyl Compounds; Cardiotonic Agents; Disease Models, Animal; Echocardiography; Fluorodeoxyglucose F18; Perindopril; Positron-Emission Tomography; Pyrimidines; Random Allocation; Swine; Tetrazoles; Tomography, Emission-Computed, Single-Photon; Valsartan; Ventricular Function, Left | 2015 |
Valsartan Attenuates Atherosclerosis via Upregulating the Th2 Immune Response in Prolonged Angiotensin II-Treated ApoE(-/-) Mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Monoclonal; Apolipoproteins E; Atherosclerosis; Blood Pressure; Body Weight; Disease Models, Animal; Inflammation; Interleukin-5; Lipids; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic; T-Lymphocyte Subsets; Th2 Cells; Valsartan | 2015 |
MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Disease Models, Animal; Endoglin; Fibrosis; Gene Expression Regulation; Hemodynamics; Heptanoic Acids; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Muscle Cells; Myocardial Infarction; Polymerase Chain Reaction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
Modulation of oxidative stress by enalapril and valsartan in adrenaline treated rats: a comparative study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Enalapril; Epinephrine; Female; Male; Oxidative Stress; Rats; Rats, Long-Evans; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in isolated ischaemia and reperfused rat hearts.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Coronary Circulation; Disease Models, Animal; Gene Expression Regulation; Male; Myocardial Reperfusion Injury; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Up-Regulation; Valine; Valsartan | 2015 |
Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Apoptosis; Arrhythmias, Cardiac; Atrial Remodeling; Benzimidazoles; Benzoates; Blood Pressure; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Heart Rate; Hypertension; Male; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; ras Proteins; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Telmisartan; Time Factors; Valsartan | 2015 |
Evaluation of Left Ventricle Function by Regional Fractional Area Change (RFAC) in a Mouse Model of Myocardial Infarction Secondary to Valsartan Treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography; Female; Gene Expression Profiling; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardium; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Valsartan Attenuates KIR2.1 by Downregulating the Th1 Immune Response in Rats Following Myocardial Infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Down-Regulation; Hemodynamics; Interferon-gamma; Interleukin-2; Male; Membrane Potentials; Myocardial Infarction; Myocytes, Cardiac; Potassium; Potassium Channels, Inwardly Rectifying; Rats, Wistar; Th1 Cells; Time Factors; Tumor Necrosis Factor-alpha; Valsartan | 2016 |
Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations.
Topics: Alzheimer Disease; Aminobutyrates; Amyloid beta-Peptides; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Brain; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haplorhini; Heart Failure; Humans; Mice; Neprilysin; Retinal Degeneration; Tetrazoles; Valsartan | 2016 |
Valsartan ameliorates KIR2.1 in rats with myocardial infarction via the NF-κB-miR-16 pathway.
Topics: Animals; Base Sequence; Cell Line; Disease Models, Animal; Hemodynamics; Male; MicroRNAs; Models, Biological; Myocardial Infarction; NF-kappa B; Potassium Channels, Inwardly Rectifying; Rats, Wistar; Reproducibility of Results; Signal Transduction; Up-Regulation; Valsartan; Ventricular Dysfunction, Left | 2016 |
Intrarenal renin-angiotensin system mediates fatty acid-induced ER stress in the kidney.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blood Glucose; Cell Line; Cell Survival; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Fumarates; Gene Expression Regulation; Heat-Shock Proteins; Humans; Kidney Diseases; Kidney Tubules, Proximal; Male; Mice, Inbred C57BL; Palmitic Acid; Renin-Angiotensin System; RNA, Messenger; Signal Transduction; Transcription Factor CHOP; Tunicamycin; Unfolded Protein Response; Valsartan | 2016 |
Valsartan attenuates cardiac and renal hypertrophy in rats with experimental cardiorenal syndrome possibly through down-regulating galectin-3 signaling.
Topics: Animals; Cardio-Renal Syndrome; Cardiomegaly; Disease Models, Animal; Down-Regulation; Echocardiography; Galectin 3; Glomerular Filtration Rate; Heart; Heart Failure; Kidney; Male; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Signal Transduction; Valsartan | 2016 |
Effect of Valsartan on Cerebellar Adrenomedullin System Dysregulation During Hypertension.
Topics: Adrenomedullin; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Catalase; Cerebellum; Disease Models, Animal; Glutathione Peroxidase; Hypertension; Male; Random Allocation; Rats, Inbred SHR; Rats, Inbred WKY; Receptor Activity-Modifying Protein 1; Receptor Activity-Modifying Protein 2; Receptor Activity-Modifying Protein 3; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Valsartan | 2017 |
Valsartan Protects Against Contrast-Induced Acute Kidney Injury in Rats by Inhibiting Endoplasmic Reticulum Stress-Induced Apoptosis.
Topics: Activating Transcription Factor 4; Acute Kidney Injury; Animals; Apoptosis; Caspase 12; Contrast Media; Cytoprotection; Diatrizoate Meglumine; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; JNK Mitogen-Activated Protein Kinases; Kidney; Male; Rats, Wistar; Renin-Angiotensin System; Signal Transduction; Time Factors; Transcription Factor CHOP; Valsartan | 2017 |
Long-Term Angiotensin II Receptor Blockade Limits Hypertension, Aortic Dysfunction, and Structural Remodeling in a Rat Model of Chronic Kidney Disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Blood Pressure; Cathepsin D; Cathepsin L; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hypertension; Kidney; Male; Matrix Metalloproteinase 9; NF-kappa B; Polycystic Kidney Diseases; Rats, Inbred Lew; Renal Insufficiency, Chronic; Time Factors; Valsartan; Vascular Remodeling; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2016 |
Effects of Angiotensin II Receptor Blockade on Soluble Klotho and Oxidative Stress in Calcineurin Inhibitor Nephrotoxicity in Rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin Receptor Antagonists; Animals; Calcineurin Inhibitors; Cyclosporine; Deoxyguanosine; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Glucuronidase; Kidney; Kidney Diseases; Klotho Proteins; Malondialdehyde; Oxidative Stress; Random Allocation; Rats; Rats, Sprague-Dawley; Spectrophotometry; Valsartan | 2016 |
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Diuretics; Fibroblasts; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Hydrochlorothiazide; Male; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Recovery of Function; Signal Transduction; Smad2 Protein; Stroke Volume; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Deletion of angiotensin II type 2 receptor attenuates protective effects of bone marrow stromal cell treatment on ischemia-reperfusion brain injury in mice.
Topics: Animals; Antihypertensive Agents; Bone Marrow Transplantation; Brain Infarction; Brain Ischemia; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Reperfusion Injury; Stromal Cells; Survival Rate; Tetrazoles; Treatment Outcome; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2008 |
[Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
Topics: Animals; Antihypertensive Agents; Apoptosis; Apoptosis Regulatory Proteins; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Immunosuppressive Agents; Kidney; Male; Mycophenolic Acid; NF-kappa B; Random Allocation; Rats; Rats, Wistar; Tetrazoles; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Valine; Valsartan | 2008 |
Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Coronary Artery Disease; Disease Models, Animal; Endothelium, Vascular; Inflammation; Lipids; Male; Rabbits; Risk; Simvastatin; Stress, Mechanical; Tetrazoles; Valine; Valsartan | 2009 |
The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Chlorhexidine; Disease Models, Animal; Enalapril; Female; Peritoneal Dialysis; Peritoneum; Rats; Rats, Wistar; Sclerosis; Tetrazoles; Valine; Valsartan | 2008 |
Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Blood Pressure; Disease Models, Animal; Disease Progression; Gene Expression Regulation; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neutrophil Infiltration; NF-kappa B; Pancreatic Elastase; Rats; Rats, Wistar; Tetrazoles; Ultrasonography; Valine; Valsartan | 2008 |
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Collagen; Disease Models, Animal; Female; Heart Rate; Hypertrophy, Left Ventricular; Ligation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocytes, Cardiac; Ramipril; Receptor, Bradykinin B1; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
[Renin-angiotensin system blocking agents reverse the myocardial hypertrophy in experimental hyperthyroid cardiomyopathy via altering intracellular calcium handling].
Topics: Animals; Calcium; Calcium Channels; Cardiomyopathies; Disease Models, Animal; Hyperthyroidism; Imidazolidines; Myocardium; Rabbits; Renin-Angiotensin System; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tetrazoles; Thyroxine; Valine; Valsartan | 2008 |
Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypertension; Linear Models; Male; Proteinuria; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2009 |
Effects of angiotensin-II receptor blockers on experimental autoimmune myocarditis.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Autoimmune Diseases; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Myocarditis; Rats; Rats, Inbred Lew; Tetrazoles; Th1 Cells; Th2 Cells; Valine; Valsartan | 2009 |
[Effects of valsartan on myocardial calcium/calmodulin-dependent protein kinase-II expression and activity in a rabbit model of heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Female; Heart Failure; Male; Myocardium; Rabbits; Tetrazoles; Valine; Valsartan | 2009 |
Involvement of Rho-kinase in collar-induced vasoconstriction and vascular hypersensitivity to serotonin in rat carotid.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II Type 1 Receptor Blockers; Animals; Carotid Artery Diseases; Cerebrovascular Circulation; Disease Models, Animal; Male; Protein Kinase Inhibitors; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; rho-Associated Kinases; rhoA GTP-Binding Protein; Serotonin; Silicones; Tetrazoles; Valine; Valsartan; Vasoconstriction | 2011 |
Metabolomics in angiotensin II-induced cardiac hypertrophy.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Biomarkers; Cardiomegaly; Disease Models, Animal; Fatty Acids; Female; Humans; Hypoxanthine; Linoleic Acids; Male; Metabolomics; Mitochondria, Heart; Oxidative Stress; Probability; Random Allocation; Rats; Rats, Sprague-Dawley; Reference Values; Sirtuin 1; Survival Rate; Tetrazoles; Valine; Valsartan | 2010 |
Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animal Feed; Animals; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Gene Expression; Glucose Intolerance; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Macrophages; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mitochondria; Tetrazoles; Valine; Valsartan | 2010 |
Valsartan alleviates atherosclerotic lesions in pulmonary arteries of rabbits via an endothelium-dependent mechanism.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Endothelium, Vascular; Lipids; Male; Nitric Oxide; Pulmonary Artery; Rabbits; Tetrazoles; Treatment Outcome; Valine; Valsartan; Vasodilation | 2010 |
RILLKKMPSV influences the vasculature, neurons and glia, and (pro)renin receptor expression in the retina.
Topics: Animals; Animals, Newborn; Cell Survival; Chymosin; Disease Models, Animal; Enzyme Precursors; Neovascularization, Physiologic; Neuroglia; Neurons; Oligopeptides; Probability; Prorenin Receptor; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Reference Values; Retina; Retinal Diseases; Retinal Vessels; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2010 |
Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse.
Topics: Angiopoietin-Like Protein 4; Angiopoietins; Angiotensin II Type 1 Receptor Blockers; Animals; Cerebral Cortex; Diabetes Mellitus; Disease Models, Animal; Gene Expression Regulation; Hypothalamus; Intra-Abdominal Fat; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Pituitary Gland; Resistin; RNA, Messenger; Subcutaneous Fat; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Local angiotensin II aggravates cardiac remodeling in hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Collagen; Desoxycorticosterone; Dinoprost; Disease Models, Animal; Heart Rate; Hypertension; Male; Membrane Glycoproteins; Mice; Mice, Transgenic; Myocardium; Myocytes, Cardiac; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2010 |
The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Glomerulonephritis; Hypertension; Kidney; Kidney Diseases; Male; Organ Size; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Temporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Arteries; Blood Vessels; Disease Models, Animal; Hydralazine; Hypertension; Mice; Mice, Inbred C57BL; NADPH Oxidases; Neointima; Oxidative Stress; Renin; Tetrazoles; Valine; Valsartan | 2011 |
Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Body Weight; Dietary Fats; Disease Models, Animal; Hypertension; Kidney Diseases; Male; Metabolic Syndrome; PPAR gamma; Rats; Rats, Inbred SHR; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Role of angiotensin-(1-7) in rostral ventrolateral medulla in blood pressure regulation via sympathetic nerve activity in Wistar-Kyoto and spontaneous hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Disease Models, Animal; Hypertension; Male; Medulla Oblongata; Microinjections; Peptide Fragments; Peptides; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan | 2011 |
Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan.
Topics: Administration, Cutaneous; Animals; Antihypertensive Agents; Disease Models, Animal; Drug Delivery Systems; Humans; Hypertension; Liposomes; Nanospheres; Particle Size; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2012 |
[Effect of valsartan and carnitine on cardiomyocyte Calpain-1 and Bcl-xl expressions of dogs with chronic alcohol intake-induced cardiomyopathy].
Topics: Animals; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Calpain; Cardiomyopathy, Alcoholic; Carnitine; Disease Models, Animal; Dogs; Myocytes, Cardiac; Tetrazoles; Valine; Valsartan | 2011 |
Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Disease Models, Animal; Drug Therapy, Combination; Fumarates; Heart Rate; Male; Motor Activity; Random Allocation; Rats; Rats, Inbred Lew; Rats, Transgenic; Receptors, Angiotensin; Renin; Tetrazoles; Valine; Valsartan | 2012 |
Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cytochrome P-450 CYP11B2; Disease Models, Animal; Drug Therapy, Combination; Fadrozole; Follow-Up Studies; Microglia; Oxygen; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Retinal Neovascularization; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomyopathy, Dilated; Cricetinae; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Fumarates; Male; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2012 |
Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Carotid Artery Diseases; Carotid Artery, Common; CD36 Antigens; Disease Models, Animal; Disease Progression; Focal Adhesion Kinase 1; Gene Deletion; JNK Mitogen-Activated Protein Kinases; Lipids; Lipoproteins, LDL; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Plaque, Atherosclerotic; Receptor, Angiotensin, Type 1; Rupture, Spontaneous; Superoxides; Tetrazoles; Time Factors; Valine; Valsartan | 2012 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, Animal; Down-Regulation; Heart Failure; Isoproterenol; Male; Myocytes, Cardiac; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Valine; Valsartan | 2013 |
Release of preformed Ang II from myocytes mediates angiotensinogen and ET-1 gene overexpression in vivo via AT1 receptor.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Aortic Valve Stenosis; Cardiac Catheterization; Cytoplasm; Disease Models, Animal; Endothelin-1; Gene Expression Regulation; Heart; Insulin-Like Growth Factor I; Microscopy, Confocal; Myocardium; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Renin-Angiotensin System; RNA, Messenger; Stress, Mechanical; Swine; Systole; Tetrazoles; Valine; Valsartan | 2002 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Hypertension; Kidney Glomerulus; Male; Membrane Proteins; Proteins; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Sclerosis; Systole; Tetrazoles; Valine; Valsartan; Verapamil | 2003 |
Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucose; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; Glucose Transporter Type 4; Hyperglycemia; Liver; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Nicorandil; Nifedipine; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Rats, Wistar; RNA, Messenger; Saralasin; Tetrazoles; Valine; Valsartan | 2003 |
Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Heart; In Situ Hybridization; Infusions, Parenteral; Male; Myocardium; Nephrectomy; NF-kappa B; Rats; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dogs; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Treatment Outcome; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2004 |
Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
Topics: Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Carotid Artery Injuries; Disease Models, Animal; Hypertension; Nitric Oxide; Oxidative Stress; Rats; Rats, Sprague-Dawley; Tetrazoles; Tunica Intima; Valine; Valsartan | 2004 |
Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Crosses, Genetic; Deoxyglucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Energy Intake; Gene Expression Regulation; Glucose Transporter Type 4; Imidazoles; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mice, Obese; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Phosphoproteins; Phosphorylation; Protein Processing, Post-Translational; Protein Transport; Pyridines; Signal Transduction; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2004 |
Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Mice; Mice, Knockout; Oxidative Stress; Tetrazoles; Valine; Valsartan | 2004 |
Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Blotting, Western; Densitometry; Disease Models, Animal; Dogs; Electrocardiography; Electrophoresis, Gel, Two-Dimensional; Heart Rate; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardial Infarction; Myocardial Reperfusion; Random Allocation; Tetrazoles; Tissue Inhibitor of Metalloproteinase-3; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression.
Topics: Administration, Oral; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cyclic N-Oxides; Disease Models, Animal; Glucose; Hypertension; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Spin Labels; Tetrazoles; Valine; Valsartan | 2005 |
Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Administration, Oral; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Body Weight; Deoxyguanosine; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Islets of Langerhans; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
[The effect of captopril and valsartan on preventing the formation of atherosclerotic plaque].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Abdominal; Arteriosclerosis; Captopril; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Male; Rabbits; Tetrazoles; Ultrasonography; Valine; Valsartan | 2005 |
[The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy].
Topics: Animals; Aristolochic Acids; Bosentan; Collagen Type I; Connective Tissue Growth Factor; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; Male; Plasminogen Activator Inhibitor 1; Rats; Rats, Sprague-Dawley; Sulfonamides; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Valine; Valsartan | 2005 |
Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Basilar Artery; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Mesenteric Arteries; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Wistar; Rosiglitazone; Simvastatin; Tetrazoles; Thiazolidinediones; Tunica Media; Valine; Valsartan | 2005 |
[Mechanism of cardioprotection against ischemia/reperfusion injury by valsartan: an experiment with isolated rat hearts].
Topics: Animals; Bradykinin; Bradykinin B2 Receptor Antagonists; Cardiotonic Agents; Creatine Kinase, MB Form; Disease Models, Animal; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B2; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2005 |
Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Topics: Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Animals; Bile; Cell Line; Cell Membrane; Disease Models, Animal; Estrone; Hepatocytes; Humans; Hyperbilirubinemia; Liver-Specific Organic Anion Transporter 1; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Rats; Rats, Sprague-Dawley; Sincalide; Solute Carrier Organic Anion Transporter Family Member 1B3; Tetrazoles; Transfection; Valine; Valsartan | 2006 |
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Animals, Genetically Modified; Blood Pressure; Disease Models, Animal; Hypertension, Renal; Kidney Glomerulus; Male; Malondialdehyde; Mice; Microscopy, Electron, Transmission; NADPH Oxidases; Neprilysin; Oxidative Stress; Peptidyl-Dipeptidase A; Podocytes; Rats; Rats, Sprague-Dawley; Renin; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2006 |
[Angiotensin II AT1 receptor antagonists as antiinflammatory and gastric protection drugs].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Benzimidazoles; Biphenyl Compounds; Carrageenan; Disease Models, Animal; Edema; Female; Gastric Mucosa; Indomethacin; Losartan; Rats; Rats, Wistar; Stomach Ulcer; Tetrazoles; Valine; Valsartan | 2006 |
Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Dendritic Cells; Disease Models, Animal; Disease Progression; Fibrosis; Immunohistochemistry; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Membrane Glycoproteins; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2006 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Diuretics; Fibrosis; Glomerulonephritis, Membranoproliferative; Ki-67 Antigen; Kidney; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Spironolactone; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Effects of angiotensin II on NO bioavailability evaluated using a catheter-type NO sensor.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Catheterization; Cyclic N-Oxides; Disease Models, Animal; Hydralazine; Male; Nitric Oxide; Oxidants; Oxidative Stress; Rabbits; Spin Labels; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents; Vasodilator Agents | 2006 |
The effects of cilazapril and valsartan on the mRNA and protein expressions of atrial calpains and atrial structural remodeling in atrial fibrillation dogs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Fibrillation; Blotting, Western; Calpain; Cilazapril; Disease Models, Animal; Dogs; Female; Gene Expression; Gene Expression Regulation; Heart Atria; Male; Myocytes, Cardiac; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Ultrasonography; Valine; Valsartan | 2007 |
Angiotensin II mediates postischemic leukocyte-endothelial interactions: role of calcitonin gene-related peptide.
Topics: Acetophenones; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcitonin Gene-Related Peptide; Captopril; Cell Adhesion; Chymases; Disease Models, Animal; Endothelial Cells; Imidazoles; Intestines; Ischemia; Leukocyte Rolling; Leukocytes; Male; Mice; Mice, Inbred C57BL; Microscopy, Video; NADPH Oxidases; Pyridines; Pyrimidinones; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Calcitonin Gene-Related Peptide; Reperfusion Injury; Tetrazoles; Valine; Valsartan; Venules | 2007 |
Contribution of different Nox homologues to cardiac remodeling in two-kidney two-clip renovascular hypertensive rats: effect of valsartan.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Ventricles; Hypertension, Renovascular; Ligation; Male; Malondialdehyde; Membrane Glycoproteins; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Rats; Rats, Sprague-Dawley; Renal Artery; Superoxides; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2007 |
Sodium, arterial stiffness, and cardiovascular mortality in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Carotid Arteries; Compliance; Disease Models, Animal; Hypertension; Male; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Tetrazoles; Time Factors; Valine; Valsartan | 2007 |
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.
Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Calcium Channel Blockers; Cell Size; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Intra-Abdominal Fat; Male; Obesity; PPAR gamma; Random Allocation; Rats; Rats, Long-Evans; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Urea Nitrogen; Blotting, Western; Creatinine; Disease Models, Animal; DNA; Heart Failure; Immunohistochemistry; Kidney Failure, Chronic; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Nephrectomy; Oxidative Stress; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Treatment Outcome; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2007 |
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blotting, Western; Collagen Type I; Disease Models, Animal; Disease Progression; Fatty Liver; Hypoglycemic Agents; Immunohistochemistry; Male; Pioglitazone; PPAR gamma; Rats; Rats, Inbred F344; Spectrophotometry; Telmisartan; Tetrazoles; Thiazolidinediones; Treatment Outcome; Valine; Valsartan | 2007 |
[Effect of cilazapril and valsartan on the levels of cardiac interstitial water content in rats with acute myocardial infarction].
Topics: Animals; Antihypertensive Agents; Cilazapril; Disease Models, Animal; Male; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2007 |
Novel mechanisms of valsartan on the treatment of acute myocardial infarction through inhibition of the antiadhesion molecule periostin.
Topics: Acute Disease; Angiotensin II; Animals; Antihypertensive Agents; Cell Adhesion Molecules; Cell Communication; Cells, Cultured; Disease Models, Animal; Fibroblasts; Gene Expression Regulation; Male; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Random Allocation; Rats; Rats, Inbred Lew; Rats, Wistar; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2007 |
NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Blood Pressure; Blotting, Western; C-Reactive Protein; Cells, Cultured; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Insulin Resistance; Male; Muscle, Smooth, Vascular; NADPH Oxidases; Probability; Random Allocation; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sensitivity and Specificity; Superoxide Dismutase; Tetrazoles; Valine; Valsartan; Vasculitis | 2007 |
Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Cell Communication; Cell Proliferation; Cells, Cultured; Collagen Type I; Culture Media; Disease Models, Animal; Dogs; Extracellular Matrix; Fibroblasts; Fibronectins; Heterocyclic Compounds, 4 or More Rings; Muscle Contraction; Myocytes, Cardiac; Tachycardia; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2007 |
Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure.
Topics: Acetophenones; Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apoptosis; Biopterins; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Endothelium, Vascular; Heart Failure, Diastolic; Hydralazine; Hypertension; Male; MAP Kinase Kinase Kinase 5; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Nitric Oxide Synthase Type III; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Signal Transduction; Sodium Chloride, Dietary; Superoxides; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilation | 2007 |
Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antihypertensive Agents; Behavior, Animal; Brain; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Memory; Mice; Mice, Transgenic; Protein Structure, Quaternary; Random Allocation; Space Perception; Tetrazoles; Valine; Valsartan | 2007 |
[Effect of valsartan on neointimal proliferation and expression of vWF after balloon angioplasty in rabbits].
Topics: Angioplasty, Balloon; Animals; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; Hyperplasia; Male; Postoperative Period; Rabbits; Random Allocation; Tetrazoles; Tunica Intima; Valine; Valsartan; von Willebrand Factor | 2007 |
An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Colitis; Cytokines; Disease Models, Animal; Humans; Immunohistochemistry; Inflammatory Bowel Diseases; Male; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2008 |
Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models.
Topics: Adipocytes, White; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Cell Differentiation; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Gene Deletion; Gene Expression; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2008 |
Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats.
Topics: Acetylcholine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Carotid Arteries; Disease Models, Animal; Hypertension; Male; NADPH Oxidases; Peptidyl-Dipeptidase A; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renin; Telmisartan; Tetrazoles; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2007 |
Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Brain Stem; Calcium Channel Blockers; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Enalapril; Hypertension; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Stroke; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
[The study of the effect of Cilazapril and valsartan on angiotensin 1 and angiotensin 2 receptors mRNA expression and myocardial interstitial collagen metabolism after myocardial infarction in rats].
Topics: Animals; Cilazapril; Collagen; Disease Models, Animal; Male; Myocardial Infarction; Myocardium; Random Allocation; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2008 |
Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Antioxidants; Apoptosis; Blood Pressure; Cyclic N-Oxides; Disease Models, Animal; Fatty Liver; Lipid Peroxidation; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Renin; Renin-Angiotensin System; Spin Labels; Tetrazoles; Valine; Valsartan | 2008 |
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardiac Output; Cardiac Pacing, Artificial; Diastole; Disease Models, Animal; Endothelins; Epinephrine; Heart Failure; Heart Rate; Hemodynamics; Norepinephrine; Pulmonary Artery; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1997 |
Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Heart Rate; Hypertension; Male; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Telemetry; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1998 |
AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiac Pacing, Artificial; Coronary Vessels; Disease Models, Animal; Exercise Test; Heart Failure; Hemodynamics; Male; Regional Blood Flow; Swine; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1998 |
Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Thoracic; Arteriosclerosis; Benzazepines; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Immunohistochemistry; Male; Muscle, Smooth, Vascular; Rabbits; Reference Values; Tetrazoles; Valine; Valsartan | 1999 |
[Contribution of the renin-angiotensin system to blood pressure variability in hyperthyroid rats].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cardiomegaly; Chronic Disease; Disease Models, Animal; Fever; Fourier Analysis; Heart Rate; Hypertension; Hyperthyroidism; Injections, Intraperitoneal; Male; Rats; Rats, Wistar; Renin; Renin-Angiotensin System; Signal Processing, Computer-Assisted; Tachycardia; Tetrazoles; Thyroid Hormones; Thyrotoxicosis; Thyroxine; Valine; Valsartan; Weight Loss | 2000 |
Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Blotting, Northern; Disease Models, Animal; Gene Expression; In Situ Hybridization; Kidney; Macrophages; Male; Nephrectomy; Nephritis, Interstitial; Osteopontin; Ramipril; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sialoglycoproteins; Tetrazoles; Valine; Valsartan | 2000 |
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Catecholamines; Collagen; Diastole; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Endothelin-1; Gene Expression; Heart Failure; Heart Function Tests; Hydroxyproline; Myocardium; Myosin Heavy Chains; Organ Size; Rats; Rats, Inbred Dahl; Receptors, Angiotensin; RNA, Messenger; Sodium Chloride, Dietary; Survival Rate; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2001 |
Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction--effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Calcium-Binding Proteins; Calpain; Disease Models, Animal; Gene Expression Regulation; Heart; Heart Rate; Imidazoles; Male; Myocardial Infarction; Protein Biosynthesis; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Transcription, Genetic; Valine; Valsartan | 2001 |
Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes.
Topics: Acetylcholine; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensive Agents; Dinoprost; Disease Models, Animal; Endothelium, Vascular; F2-Isoprostanes; Humans; Hypertension; Ketone Oxidoreductases; Male; Nitrates; Nitrites; Nitroprusside; Norepinephrine; Rats; Rats, Sprague-Dawley; Renal Artery; Renin; Superoxide Dismutase; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents; Vasodilation | 2001 |
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Basement Membrane; Blood Pressure; Diabetes Mellitus, Experimental; Disease Models, Animal; Disease Progression; Humans; Kidney; Kidney Glomerulus; Male; Organ Size; Ramipril; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2001 |
Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Malignant; Hypertension, Renovascular; Immunohistochemistry; Kidney; Macrophages; Male; Nephritis; Organ Size; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Survival Rate; Tetrazoles; Valine; Valsartan | 2001 |
Valsartan improves fibrinolytic balance in atherosclerotic rabbits.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Arteriosclerosis; Biomarkers; Blood Pressure; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Dose-Response Relationship, Drug; Factor VIII; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Hypercholesterolemia; Male; Myocardial Contraction; Rabbits; Tetrazoles; Time; Treatment Outcome; Valine; Valsartan | 2002 |